Cross-source evidence timeline

Trofinetide research timeline

Follow 27 selected, directly cited source records from August 14, 2020 through October 1, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

27Selected records
5Source years
3Evidence lanes
October 1, 2026Latest source date

Source year

2026

11 records
  1. Literature metadata

    Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.↗

    PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.↗

    PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.↗

    PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.↗

    PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.↗

    PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method.↗

    PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues.↗

    PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy.↗

    PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Rett syndrome and real-world treatment patterns of trofinetide in the United States.↗

    PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Trofinetide treatment for Rett syndrome: Lessons to learn.↗

    PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.↗

    PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

3 records
  1. Regulatory

    Drugs@FDA application NDA219884↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.↗

  2. Literature metadata

    Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.↗

    PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials.↗

    PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

8 records
  1. Literature metadata

    Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.↗

    PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Trofinetide: a pioneering treatment for Rett syndrome.↗

    PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Federal Register notice 2024-21941↗

    The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.↗

  4. Literature metadata

    Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome.↗

    PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Trofinetide (Daybue) for Rett syndrome.↗

    PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome.↗

    PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT04279314↗

    PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04181723↗

    PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.↗

Source year

2023

4 records
  1. Literature metadata

    Trofinetide-a new chapter in rett syndrome's treatment.↗

    PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Trofinetide.↗

    PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Regulatory

    Federal Register notice 2023-06593↗

    The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.↗

  4. Regulatory

    Drugs@FDA application NDA217026↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.↗

Source year

2020

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT02715115↗

    PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.↗